Drugs / ELX-02
ELX-02
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03776539 | Jan → Jul 2019 | impaired renal function disease | Eloxx Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03309605 | Oct 2017 → Jun 2019 | disease of genetic or genomic mechanism | Eloxx Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07523581 | Jun 2026 → Jun 2027 expected | X-linked Alport syndrome, autosomal recessive Alport syndrome | Eloxx Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05448755 | Nov 2022 → Sep 2023 | Alport syndrome | Eloxx Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04135495 | Nov 2019 → Oct 2022 | cystic fibrosis | Eloxx Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04126473 | Nov 2019 → Apr 2022 | cystic fibrosis | Eloxx Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04069260 | Aug → Dec 2019 | cystinosis | Eloxx Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03292302 Comparator | Sep → Dec 2017 | disease of genetic or genomic mechanism | Eloxx Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02807961 Comparator | Jul 2016 → Feb 2017 | disease of genetic or genomic mechanism | Eloxx Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELX-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04135495 ↗ |
| Known as | Exaluren | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07523581 ↗ |
| Known as | Exalurene | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297744 ↗ |
| Known as | Exalureno | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297744 ↗ |
| Known as | NB-124 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297744 ↗ |
| Action | Restore | “optimized as a translational read-through drug (TRID) for the treatment of genetic conditions caused by nonsense mutations” NCT03292302 ↗ |
| Modality | Small molecule | “advanced synthetic aminoglycoside” NCT02807961 ↗ |
| Route | Subcutaneous | “Subcutaneously Administered ELX-02” NCT03309605 ↗ |